Setting

Europe Injectable Drugs Market 2020-2030 by Molecule Type (Small, Large), Drug Class (mAbs, Immunoglobulin, Insulin, Vaccines, Cytokines, Peptide Hormone, Blood Factors), Delivery (Pre-filled Syringe, Infusions, Others), Application (Oncology, Infectious Diseases, Autoimmune, Cardiovascular), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce), and Country: Trend Forecast and Growth Opportunity

Published: 30 Nov 2021 | Report Code: 10248272 | Pages: 111

Europe injectable drugs market was valued at $104.8 billion in 2020 and will grow by 9.7% annually over 2020-2030 owing to the increasing prevalence of chronic diseases, rising use of self-administered Injectable formulations, technological advancements in drug development, and growing approvals of new injectable drugs such as COVID-19 vaccines. Highlighted with 33 tables and 54 figures, this 111-page report “Europe Injectable Drugs Market 2020-2030 by Molecule Type (Small, Large), Drug Class (mAbs, Immunoglobulin, Insulin, Vaccines, Cytokines, Peptide Hormone, Blood Factors), Delivery (Pre-filled Syringe, Infusions, Others), Application (Oncology, Infectious Diseases, Autoimmune, Cardiovascular), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Commerce), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe injectable drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19). In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe injectable drugs market in every aspect of the classification from perspectives of Molecule Type, Drug Class, Delivery, Application, Distribution Channel, and Country. Based on Molecule Type, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Small Molecule • Large Molecule Based on Drug Class, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Monoclonal Antibodies (mAbs) • Immunoglobulin • Insulin • Vaccines • Cytokines • Peptide Hormone • Blood Factors • Other Drug Classes Based on Delivery, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Pre-filled Syringe • Infusions • Other Deliveries Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Oncology • Infectious Diseases • Autoimmune Diseases • Cardiovascular Diseases • Pain • Neurology • Other Applications Based on Distribution Channel, the Europe market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section. • Hospital Pharmacy • Retail Pharmacy • E-Commerce Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Molecule Type, Drug Class, and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Amgen Inc. Baxter International Inc. Eli Lilly and Company Gilead Sciences Inc. GlaxoSmithKline PLC Johnson & Johnson Merck & Co. Inc. Moderna, Inc. Novartis AG Novo Nordisk AS Pfizer Inc. Sanofi SA Teva Pharmaceuticals Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:
1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	13
1.2.6 Market Size/Share Estimation	14
1.2.7 Research Limitations	15
1.3 Executive Summary	16
2 Market Overview and Dynamics	19
2.1 Market Size and Forecast	19
2.1.1 Impact of COVID-19 on World Economy	20
2.1.2 Impact of COVID-19 on the Market	23
2.2 Major Growth Drivers	25
2.3 Market Restraints and Challenges	30
2.4 Emerging Opportunities and Market Trends	33
2.5 Porter’s Fiver Forces Analysis	37
3 Segmentation of Europe Market by Molecule Type	41
3.1 Market Overview by Molecule Type	41
3.2 Small Molecule	43
3.3 Large Molecule	44
4 Segmentation of Europe Market by Drug Class	45
4.1 Market Overview by Drug Class	45
4.2 Monoclonal Antibodies (mAbs)	47
4.3 Immunoglobulin	48
4.4 Insulin	49
4.5 Vaccines	50
4.6 Cytokines	51
4.7 Peptide Hormone	52
4.8 Blood Factors	53
4.9 Other Drug Classes	54
5 Segmentation of Europe Market by Delivery	55
5.1 Market Overview by Delivery	55
5.2 Pre-filled Syringe	57
5.3 Infusions	58
5.4 Other Deliveries	59
6 Segmentation of Europe Market by Application	60
6.1 Market Overview by Application	60
6.2 Oncology	62
6.3 Infectious Diseases	63
6.4 Autoimmune Diseases	64
6.5 Cardiovascular Diseases	65
6.6 Pain	66
6.7 Neurology	67
6.8 Other Applications	68
7 Segmentation of Europe Market by Distribution Channel	69
7.1 Market Overview by Distribution Channel	69
7.2 Hospital Pharmacy	71
7.3 Retail Pharmacy	72
7.4 E-Commerce	73
8 European Market 2019-2030 by Country	74
8.1 Overview of European Market	74
8.2 Germany	77
8.3 U.K.	79
8.4 France	82
8.5 Spain	84
8.6 Italy	86
8.7 Russia	88
8.8 Rest of European Market	91
9 Competitive Landscape	93
9.1 Overview of Key Vendors	93
9.2 New Product Launch, Partnership, Investment, and M&A	96
9.3 Company Profiles	97
Amgen Inc.	97
Baxter International Inc.	99
Eli Lilly and Company	100
Gilead Sciences Inc.	101
GlaxoSmithKline PLC	102
Johnson & Johnson	103
Merck & Co. Inc.	104
Moderna, Inc.	105
Novartis AG	106
Novo Nordisk AS	107
Pfizer Inc.	108
Sanofi SA	109
Teva Pharmaceuticals Industries Ltd.	110
RELATED REPORTS	111
?
List Of Tables:

Table 1.  Snapshot of Europe Injectable Drugs Market in Balanced Perspective, 2019-2030	17
Table 2. Growth Rate of World GDP, 2020-2022	21
Table 3. World Health Spending by Region, $ bn, 2013-2020	29
Table 4.  Main Product Trends and Market Opportunities in Europe Injectable Drugs Market	33
Table 5. Europe Injectable Drugs Market by Molecule Type, 2019-2030, $ bn	41
Table 6. Europe Injectable Drugs Market by Drug Class, 2019-2030, $ bn	45
Table 7. Europe Injectable Drugs Market by Delivery, 2019-2030, $ bn	55
Table 8. Europe Injectable Drugs Market by Application, 2019-2030, $ bn	60
Table 9. Europe Injectable Drugs Market by Distribution Channel, 2019-2030, $ bn	69
Table 10. Europe Injectable Drugs Market by Country, 2019-2030, $ bn	76
Table 11. Germany Injectable Drugs Market by Molecule Type, 2019-2030, $ bn	78
Table 12. Germany Injectable Drugs Market by Drug Class, 2019-2030, $ bn	78
Table 13. Germany Injectable Drugs Market by Application, 2019-2030, $ bn	78
Table 14. U.K. Injectable Drugs Market by Molecule Type, 2019-2030, $ bn	81
Table 15. U.K. Injectable Drugs Market by Drug Class, 2019-2030, $ bn	81
Table 16. U.K. Injectable Drugs Market by Application, 2019-2030, $ bn	81
Table 17. France Injectable Drugs Market by Molecule Type, 2019-2030, $ bn	83
Table 18. France Injectable Drugs Market by Drug Class, 2019-2030, $ bn	83
Table 19. France Injectable Drugs Market by Application, 2019-2030, $ bn	83
Table 20. Spain Injectable Drugs Market by Molecule Type, 2019-2030, $ bn	85
Table 21. Spain Injectable Drugs Market by Drug Class, 2019-2030, $ bn	85
Table 22. Spain Injectable Drugs Market by Application, 2019-2030, $ bn	85
Table 23. Italy Injectable Drugs Market by Molecule Type, 2019-2030, $ bn	87
Table 24. Italy Injectable Drugs Market by Drug Class, 2019-2030, $ bn	87
Table 25. Italy Injectable Drugs Market by Application, 2019-2030, $ bn	87
Table 26. Russia Injectable Drugs Market by Molecule Type, 2019-2030, $ bn	89
Table 27. Russia Injectable Drugs Market by Drug Class, 2019-2030, $ bn	89
Table 28. Russia Injectable Drugs Market by Application, 2019-2030, $ bn	89
Table 29. Injectable Drugs Market in Rest of Europe by Country, 2019-2030, $ bn	92
Table 30. Amgen Inc.: Company Snapshot	97
Table 31. Amgen Inc.: Business Segmentation	97
Table 32. Amgen Inc.: Product Portfolio	98
Table 33. Amgen Inc.: Revenue, 2018-2020, $ bn	98
List Of Figures:

Figure 1. Research Method Flow Chart	11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	14
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030	16
Figure 4. Europe Injectable Drugs Market, 2019-2030, $ bn	19
Figure 5. Impact of COVID-19 on Business	23
Figure 6. Primary Drivers and Impact Factors of Europe Injectable Drugs Market	25
Figure 7.  Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million	28
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060	28
Figure 9. Primary Restraints and Impact Factors of Europe Injectable Drugs Market	30
Figure 10. Investment Opportunity Analysis	34
Figure 11. Porter’s Fiver Forces Analysis of Europe Injectable Drugs Market	37
Figure 12. Breakdown of Europe Injectable Drugs Market by Molecule Type, 2019-2030, % of Revenue	42
Figure 13. Europe Addressable Market Cap in 2021-2030 by Molecule Type, Value ($ bn) and Share (%)	42
Figure 14. Europe Injectable Drugs Market by Molecule Type: Small Molecule, 2019-2030, $ bn	43
Figure 15. Europe Injectable Drugs Market by Molecule Type: Large Molecule, 2019-2030, $ bn	44
Figure 16. Breakdown of Europe Injectable Drugs Market by Drug Class, 2019-2030, % of Sales Revenue	46
Figure 17. Europe Addressable Market Cap in 2021-2030 by Drug Class, Value ($ bn) and Share (%)	46
Figure 18. Europe Injectable Drugs Market by Drug Class: Monoclonal Antibodies (mAbs), 2019-2030, $ bn	47
Figure 19. Europe Injectable Drugs Market by Drug Class: Immunoglobulin, 2019-2030, $ bn	48
Figure 20. Europe Injectable Drugs Market by Drug Class: Insulin, 2019-2030, $ bn	49
Figure 21. Europe Injectable Drugs Market by Drug Class: Vaccines, 2019-2030, $ bn	50
Figure 22. Europe Injectable Drugs Market by Drug Class: Cytokines, 2019-2030, $ bn	51
Figure 23. Europe Injectable Drugs Market by Drug Class: Peptide Hormone, 2019-2030, $ bn	52
Figure 24. Europe Injectable Drugs Market by Drug Class: Blood Factors, 2019-2030, $ bn	53
Figure 25. Europe Injectable Drugs Market by Drug Class: Other Drug Classes, 2019-2030, $ bn	54
Figure 26. Breakdown of Europe Injectable Drugs Market by Delivery, 2019-2030, % of Sales Revenue	56
Figure 27. Europe Addressable Market Cap in 2021-2030 by Delivery, Value ($ bn) and Share (%)	56
Figure 28. Europe Injectable Drugs Market by Delivery: Pre-filled Syringe, 2019-2030, $ bn	57
Figure 29. Europe Injectable Drugs Market by Delivery: Infusions, 2019-2030, $ bn	58
Figure 30. Europe Injectable Drugs Market by Delivery: Other Deliveries, 2019-2030, $ bn	59
Figure 31. Breakdown of Europe Injectable Drugs Market by Application, 2019-2030, % of Revenue	61
Figure 32. Europe Addressable Market Cap in 2021-2030 by Application, Value ($ bn) and Share (%)	61
Figure 33. Europe Injectable Drugs Market by Application: Oncology, 2019-2030, $ bn	62
Figure 34. Europe Injectable Drugs Market by Application: Infectious Diseases, 2019-2030, $ bn	63
Figure 35. Europe Injectable Drugs Market by Application: Autoimmune Diseases, 2019-2030, $ bn	64
Figure 36. Europe Injectable Drugs Market by Application: Cardiovascular Diseases, 2019-2030, $ bn	65
Figure 37. Europe Injectable Drugs Market by Application: Pain, 2019-2030, $ bn	66
Figure 38. Europe Injectable Drugs Market by Application: Neurology, 2019-2030, $ bn	67
Figure 39. Europe Injectable Drugs Market by Application: Other Applications, 2019-2030, $ bn	68
Figure 40. Breakdown of Europe Injectable Drugs Market by Distribution Channel, 2019-2030, % of Revenue	70
Figure 41. Europe Addressable Market Cap in 2021-2030 by Distribution Channel, Value ($ bn) and Share (%)	70
Figure 42. Europe Injectable Drugs Market by Distribution Channel: Hospital Pharmacy, 2019-2030, $ bn	71
Figure 43. Europe Injectable Drugs Market by Distribution Channel: Retail Pharmacy, 2019-2030, $ bn	72
Figure 44. Europe Injectable Drugs Market by Distribution Channel: E-Commerce, 2019-2030, $ bn	73
Figure 45. Breakdown of European Injectable Drugs Market by Country, 2019 and 2030, % of Revenue	75
Figure 46. Contribution to Europe 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%)	76
Figure 47.  Injectable Drugs Market in Germany, 2019-2030, $ bn	77
Figure 48.  Injectable Drugs Market in U.K., 2019-2030, $ bn	79
Figure 49.  Injectable Drugs Market in France, 2019-2030, $ bn	82
Figure 50.  Injectable Drugs Market in Spain, 2019-2030, $ bn	84
Figure 51.  Injectable Drugs Market in Italy, 2019-2030, $ bn	86
Figure 52.  Injectable Drugs Market in Russia, 2019-2030, $ bn	88
Figure 53.  Injectable Drugs Market in Rest of Europe, 2019-2030, $ bn	91
Figure 54. Growth Stage of Europe Injectable Drugs Industry over the Forecast Period	93
Key Players (this may not be a complete list and extra companies can be added upon request): 
Amgen Inc.
Baxter International Inc.
Eli Lilly and Company
Gilead Sciences Inc.
GlaxoSmithKline PLC
Johnson & Johnson
Merck & Co. Inc.
Moderna, Inc.
Novartis AG
Novo Nordisk AS
Pfizer Inc.
Sanofi SA
Teva Pharmaceuticals Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)